JP5001180B2 - 自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ - Google Patents
自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ Download PDFInfo
- Publication number
- JP5001180B2 JP5001180B2 JP2007557312A JP2007557312A JP5001180B2 JP 5001180 B2 JP5001180 B2 JP 5001180B2 JP 2007557312 A JP2007557312 A JP 2007557312A JP 2007557312 A JP2007557312 A JP 2007557312A JP 5001180 B2 JP5001180 B2 JP 5001180B2
- Authority
- JP
- Japan
- Prior art keywords
- egf
- ghrp
- day
- medicament
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 title claims description 3
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title claims description 3
- 210000003169 central nervous system Anatomy 0.000 title abstract description 19
- 230000008929 regeneration Effects 0.000 title description 8
- 238000011069 regeneration method Methods 0.000 title description 8
- 210000005036 nerve Anatomy 0.000 title description 6
- 208000023275 Autoimmune disease Diseases 0.000 title description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 21
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 9
- 239000000122 growth hormone Substances 0.000 claims abstract description 9
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 6
- 206010012305 Demyelination Diseases 0.000 claims abstract description 5
- 102000018997 Growth Hormone Human genes 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 7
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000005784 autoimmunity Effects 0.000 claims description 3
- 210000002501 natural regulatory T cell Anatomy 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000016273 neuron death Effects 0.000 claims description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract description 70
- 101800003838 Epidermal growth factor Proteins 0.000 abstract description 69
- 229940116977 epidermal growth factor Drugs 0.000 abstract description 69
- 230000006378 damage Effects 0.000 abstract description 8
- 230000001363 autoimmune Effects 0.000 abstract description 4
- 230000035771 neuroregeneration Effects 0.000 abstract description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 68
- 241001465754 Metazoa Species 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 18
- 210000004248 oligodendroglia Anatomy 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 206010033799 Paralysis Diseases 0.000 description 16
- 210000000278 spinal cord Anatomy 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 210000003141 lower extremity Anatomy 0.000 description 12
- 210000001130 astrocyte Anatomy 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 8
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000007489 histopathology method Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102100038803 Somatotropin Human genes 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 210000005012 myelin Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000006472 autoimmune response Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000011694 lewis rat Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 206010013647 Drowning Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 230000003210 demyelinating effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 210000005070 sphincter Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004766 neurogenesis Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 206010057361 Blood brain barrier defect Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101500023492 Lithobates catesbeianus Growth hormone-releasing peptide Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009843 endothelial lesion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009688 glial response Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、医薬、さらに特に神経学に関連する医薬に関する。さらに自己免疫障害後、特に多発性硬化症及び視神経脊髄炎被患患者における処置及び再発の防止のために、上皮成長因子(Epidermal Growth Factor)及び成長ホルモン放出性ペプチド−6(Growth Hormome Releasing Peptide−6)を含有する組成物を投与することによって中枢神経系神経再生を刺激することに関する。
多発性硬化症(Multiple Sclerosis)(MS)及び視神経脊髄炎(Optic Neuromyelitis)(ON)は若年の人々、本質的に女性が被患する自己免疫性脱髄病であり、好ましくない時点で発生する無力及び虚脱をもたらす。MS発生数は先進国における工業化及び発展の進行パラメータに強力に相関する。
治療有効濃度のEGF及び分泌促進性GHRP−6を必要とする組合わせの投与は、動脈血液供給欠乏による組織損傷の予防及び処置に従来から示唆されてきた(WO02/053167)。
本発明は、CNSの自己免疫障害に対しEGF及びGHRP−6の共同投与を必要とする方法及び改善された処置に基づいている。この組合わせは、CNSの慢性的病状、特に多発性硬化症及び視神経脊髄炎における自己免疫付随障害を防止し、また回復させる。
本発明のもうひとつの設定において、多発性硬化症の再発を防止するために発症間段階期間内に投与される用量は、130日までの期間で各成分について0.5〜50μg/kg/日の範囲である。当該組合わせは一団として投与されなければならない。投与経路は非経口、末梢血管、筋肉内又は腹腔内である。投与に含まれるベヒクルは、正常塩類溶液、ラクテートリンゲル溶液、ヒト血漿、ヒトアルブミン溶液、デキストロース5%、ゼラチン溶液又はその混合物を包含する。
その他の多発性硬化症臨床形態において、治療的用量を用いる持続処置計画が薦められる。
EGF/GHRP−6組合わせは、単独の医薬組成物内に入れて、又は使用の直前に各成分を混合することによって使用することができる。当該活性成分組合わせは、徐放性用具の手段を用いることができる。製剤が凍結乾燥されている場合、これは使用直前に希釈しなければならない。
例1:実験的自己免疫性脳炎(EAE)バイオモデルにおけるEGF/GHRP−6医薬組合わせの治療効果
EGF/GHRP−6医薬組合わせの治療効果を評価するために、EAE動物モデルを用意した。このモデルは多発性硬化症ヒト疾病の動物等価体であった。
雌ルイスラット(Lewis Rats)(130g)を、PBS(50%)及び完全フロイントアジュバント(50%)中のモルモット脊髄ホモジネート(5mg)により0〜6日間、皮下免疫化した。最初の免疫化後の10日、EGF/GHRP−6組合わせ(200μg/kg/日−740μg/kg/日)、個別活性成分EGF(200μg/kg/日)、GHRP−6(740μg/kg/日)及びプラセボ(PBS)を用いて治療計画を開始した。
MSヒト疾病を代表するEAE動物モデルにおけるEGF/GHRP−6組合わせの予防効果を評価するために、雌ルイスラット(130g)を、PBS(50%)及び完全フロイントアジュバント(50%)中のモルモット脊髄ホモジネート(5mg)により0日目及び6日目に、皮下免疫化した。最初の免疫化前の10日の時点で、EGF/GHRP−6組合わせ(200μg/kg/日−740μg/kg/日)及び個別活性成分EGF(200μg/kg/日)、GHRP−6(740μg/kg/日)及びプラセボ(PBS)を用いる予防計画を開始した。
当該医薬組合わせが治療効果にかかわり有効である用量範囲を探求するために、前記EAEモデル、雌ルイスラット(130g)を使用し、0日〜6日間、PBS(50%)及び完全フロイントアジュバント(50%)中のモルモット脊髄ホモジネート(5mg)を用いて皮下免疫化した。最初の免疫化後の10日目に、相違する濃度で組合わされているEGF/GHRP−6組合わせを使用し、治療計画を開始した:
EGF/GHRP−6(400μg/kg/日−1480μg/kg/日)、
EGF/GHRP−6(200μg/kg/日−740μg/kg/日)、
EGF/GHRP−6(100μg/kg/日−340μg/kg/日)、
EGF/GHRP−6(50μg/kg/日−170μg/kg/日)、
EGF/GHRP−6(25μg/kg/日−85μg/kg/日)、
EGF/GHRP−6(12μg/kg/日−40μg/kg/日)。
EGF/GHRP−6(50μg/kg/日−170μg/kg/日)処置群において、動物の100%がEAEを発現し、12.5%が中間的臨床形態(2)を示し、そして残りは軽度の形態(0.5〜1)で当該疾病を示した。平均臨床指数は0.93±0.49であった。
EGF/GHRP−6(12μg/kg/日−40μg/kg/日)処置群において、動物の100%がEAEを発現し、12.5%が最も重篤な臨床形態(3)を示し、37.5%が中間的臨床形態(2)を示し、そして残りは軽度の状態(0.5〜1)で当該疾病を示した。平均臨床指数は1.37±0.87であった。
20匹の雌ルイスラット(130g)を、PBS(50%)及び完全フロイントアジュバント(50%)中のモルモット脊髄ホモジネート(5mg)により0日目に及び6日目に皮下免疫化した。最初の免疫化後の10日目に、EGF/GHRP−6組合わせ(200μg/kg/日−740μg/kg/日)を用いて治療計画を開始し、次いでこれらの免疫化したラットの中の10匹(グループA)に次の10日間、その腹腔内投与を行った。別の10匹のラットはプラセボとしてPBS処置した(グループB)。最後の投与後の1週間、両群からの動物を麻酔して採血し、これにより末梢血液単核リンパ球を得た。グループA及びグループBから得られたリンパ球を処理し、CD4+細胞を分離した。
CD4+CD25+細胞のFACSによる分析はグループAで14.67%及びPBS処置群(グループB)で3.8%であった。
Claims (7)
- 自己免疫を原因とするアポトーシス又は壊死による脱髄、ニューロン変性及びニューロン細胞死に関連する症状又は合併症に被患している患者における多発性硬化症の処置及び改善のためのEGF及び成長ホルモン放出性ペプチド−6(GHRP−6)を含む医薬。
- 前記EGFがヒトEGFである、請求項1に記載の医薬。
- 前記ヒトEGFは、合成、天然又は組換えによって得られるものである、請求項2に記載の医薬。
- EGF−GHRP−6組合わせは静脈内、筋肉内又は腹腔内投与されるものであるか、又は制御放出性用具を用いて投与されるものである、請求項1〜3のいずれか一項に記載の医薬。
- 前記医薬は、患者の体重キログラム1日当たりにおける各成分を独立して5〜10μgの用量範囲で20〜30日間にわたる治療計画で非経口投与されるものである、請求項1〜4のいずれか一項に記載の医薬。
- 前記医薬は、寛解期間中、患者の体重キログラム1日当たりで各独立成分を1〜5μgの用量範囲で130日までの期間にわたり非経口投与されるものである、請求項1〜5のいずれか一項に記載の医薬。
- 前記医薬が天然調節T細胞の増殖を誘発するものである、請求項1に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2005-0043 | 2005-03-02 | ||
CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
PCT/CU2006/000001 WO2006092106A2 (es) | 2005-03-02 | 2006-02-24 | Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531607A JP2008531607A (ja) | 2008-08-14 |
JP5001180B2 true JP5001180B2 (ja) | 2012-08-15 |
Family
ID=40280698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557312A Expired - Fee Related JP5001180B2 (ja) | 2005-03-02 | 2006-02-24 | 自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100093616A1 (ja) |
EP (1) | EP1870106B1 (ja) |
JP (1) | JP5001180B2 (ja) |
KR (1) | KR101255200B1 (ja) |
CN (1) | CN101180044B (ja) |
AT (1) | ATE431743T1 (ja) |
AU (1) | AU2006220154B2 (ja) |
BR (1) | BRPI0607844B8 (ja) |
CA (1) | CA2600628C (ja) |
CU (1) | CU23529A1 (ja) |
DE (1) | DE602006006903D1 (ja) |
ES (1) | ES2327562T3 (ja) |
MX (1) | MX2007010717A (ja) |
MY (1) | MY142494A (ja) |
PT (1) | PT1870106E (ja) |
RU (1) | RU2403913C2 (ja) |
WO (1) | WO2006092106A2 (ja) |
ZA (1) | ZA200707020B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
CU24591B1 (es) * | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
ES2967696T3 (es) | 2019-04-08 | 2024-05-03 | Giuseppe Scalabrino | Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
JP3993560B2 (ja) * | 2001-08-30 | 2007-10-17 | ステム セル セラピューティクス インコーポレイテッド | 神経幹細胞の分化およびその治療用途 |
HK1077740A1 (en) * | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
EP1506997A1 (en) * | 2003-08-14 | 2005-02-16 | NeuroProgen GmbH Leipzig | Method of generating neural stem cells |
-
2005
- 2005-03-02 CU CU20050043A patent/CU23529A1/es active IP Right Grant
-
2006
- 2006-02-24 MX MX2007010717A patent/MX2007010717A/es active IP Right Grant
- 2006-02-24 KR KR1020077022024A patent/KR101255200B1/ko active IP Right Grant
- 2006-02-24 AT AT06705745T patent/ATE431743T1/de not_active IP Right Cessation
- 2006-02-24 DE DE602006006903T patent/DE602006006903D1/de active Active
- 2006-02-24 JP JP2007557312A patent/JP5001180B2/ja not_active Expired - Fee Related
- 2006-02-24 ES ES06705745T patent/ES2327562T3/es active Active
- 2006-02-24 BR BRPI0607844A patent/BRPI0607844B8/pt not_active IP Right Cessation
- 2006-02-24 CA CA2600628A patent/CA2600628C/en not_active Expired - Fee Related
- 2006-02-24 EP EP06705745A patent/EP1870106B1/en active Active
- 2006-02-24 PT PT06705745T patent/PT1870106E/pt unknown
- 2006-02-24 MY MYPI20060792A patent/MY142494A/en unknown
- 2006-02-24 US US11/885,330 patent/US20100093616A1/en not_active Abandoned
- 2006-02-24 AU AU2006220154A patent/AU2006220154B2/en not_active Ceased
- 2006-02-24 CN CN2006800139592A patent/CN101180044B/zh active Active
- 2006-02-24 WO PCT/CU2006/000001 patent/WO2006092106A2/es active Application Filing
- 2006-02-24 RU RU2007136280/15A patent/RU2403913C2/ru active
-
2007
- 2007-08-21 ZA ZA200707020A patent/ZA200707020B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MY142494A (en) | 2010-11-30 |
KR20070107790A (ko) | 2007-11-07 |
CU23529A1 (es) | 2010-06-17 |
KR101255200B1 (ko) | 2013-04-23 |
ZA200707020B (en) | 2009-08-26 |
AU2006220154B2 (en) | 2010-05-27 |
CN101180044A (zh) | 2008-05-14 |
EP1870106B1 (en) | 2009-05-20 |
WO2006092106A2 (es) | 2006-09-08 |
CA2600628A1 (en) | 2006-09-08 |
CA2600628C (en) | 2013-04-09 |
MX2007010717A (es) | 2007-10-12 |
BRPI0607844B8 (pt) | 2021-05-25 |
PT1870106E (pt) | 2009-08-25 |
ATE431743T1 (de) | 2009-06-15 |
DE602006006903D1 (de) | 2009-07-02 |
BRPI0607844A2 (pt) | 2010-10-19 |
ES2327562T3 (es) | 2009-10-30 |
EP1870106A2 (en) | 2007-12-26 |
RU2007136280A (ru) | 2009-04-10 |
BRPI0607844B1 (pt) | 2018-08-28 |
CN101180044B (zh) | 2010-12-08 |
US20100093616A1 (en) | 2010-04-15 |
AU2006220154A1 (en) | 2006-09-08 |
WO2006092106A3 (es) | 2006-12-14 |
RU2403913C2 (ru) | 2010-11-20 |
JP2008531607A (ja) | 2008-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schwartz et al. | Immune-based therapy for spinal cord repair: autologous macrophages and beyond | |
Rabchevsky et al. | Basic fibroblast growth factor (bFGF) enhances tissue sparing and functional recovery following moderate spinal cord injury | |
Lewis et al. | Insulin-like growth factor-I: potential for treatment of motor neuronal disorders | |
Tsai et al. | Anti-apoptotic effects of human granulocyte colony-stimulating factor (G-CSF) on retinal ganglion cells after optic nerve crush are PI3K/AKT-dependent | |
Liu et al. | Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis | |
EP1827108B1 (en) | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 | |
US6780848B2 (en) | Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease | |
JP2010138203A (ja) | 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン | |
AU2010257389A1 (en) | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects | |
CA2656463C (en) | Method of treatment of age-related macular degeneration | |
JP5001180B2 (ja) | 自己免疫障害後の中枢神経系の神経再生に用いるegf/ghrp−6の組合せ | |
Bordet et al. | Mechanism of action of s1p receptor modulators in multiple sclerosis: the double requirement | |
KR0159046B1 (ko) | 포유류의 자기면역 포도막망막염의 치료 또는 예방방법 | |
US9149509B2 (en) | Methods for improving neurological outcome after neural injury and neurodegenerative disease | |
del Barco et al. | Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis | |
KR20140038383A (ko) | 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법 | |
JP2019530741A5 (ja) | ||
RU2741018C1 (ru) | Способ повышения уровня сознания пациентов в вегетативном состоянии | |
EP2498794A1 (en) | Method of treatment of type 2 diabetes | |
AU700838C (en) | Composition and methods to improve neural outcome | |
Chu et al. | Optimum pharmacologic management of an acute spinal cord injury in the setting of a lumbar burst fracture | |
Zierhut et al. | Perspectives in Immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110928 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120420 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120424 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120517 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5001180 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150525 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |